1.3. Incretin Receptor Expression in β-Cells Is Downregulated under Diabetic Conditions: Incretin-Based Agents Exert More Protective Effects on β-Cells at an Early Stage of Diabetes rather than an Advanced Stage. The gene discussed is GCG; the disease is diabetes mellitus.